nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—CYP2D6—breast cancer	0.157	1	CbGaD
Methotrimeprazine—Dimetacrine—Tamoxifen—breast cancer	0.135	0.571	CrCrCtD
Methotrimeprazine—Promazine—Tamoxifen—breast cancer	0.102	0.429	CrCrCtD
Methotrimeprazine—CYP1A2—Anastrozole—breast cancer	0.0434	0.194	CbGbCtD
Methotrimeprazine—CYP1A2—Toremifene—breast cancer	0.0397	0.178	CbGbCtD
Methotrimeprazine—CYP2D6—Idarubicin—breast cancer	0.0271	0.121	CbGbCtD
Methotrimeprazine—CYP2E1—Tamoxifen—breast cancer	0.0251	0.112	CbGbCtD
Methotrimeprazine—CYP2E1—Mitoxantrone—breast cancer	0.0244	0.11	CbGbCtD
Methotrimeprazine—CYP1A2—Tamoxifen—breast cancer	0.0145	0.065	CbGbCtD
Methotrimeprazine—CYP2D6—Vinorelbine—breast cancer	0.0132	0.0593	CbGbCtD
Methotrimeprazine—CYP2D6—Tamoxifen—breast cancer	0.0119	0.0535	CbGbCtD
Methotrimeprazine—CYP1A2—Fluorouracil—breast cancer	0.0107	0.0479	CbGbCtD
Methotrimeprazine—Necrotising enterocolitis neonatal—Paclitaxel—breast cancer	0.00907	0.0519	CcSEcCtD
Methotrimeprazine—Necrotizing enterocolitis—Paclitaxel—breast cancer	0.00907	0.0519	CcSEcCtD
Methotrimeprazine—CYP2D6—Vinblastine—breast cancer	0.00815	0.0365	CbGbCtD
Methotrimeprazine—Necrotising enterocolitis neonatal—Docetaxel—breast cancer	0.00769	0.044	CcSEcCtD
Methotrimeprazine—Necrotizing enterocolitis—Docetaxel—breast cancer	0.00769	0.044	CcSEcCtD
Methotrimeprazine—Necrotizing enterocolitis—Capecitabine—breast cancer	0.00745	0.0426	CcSEcCtD
Methotrimeprazine—Necrotising enterocolitis neonatal—Capecitabine—breast cancer	0.00745	0.0426	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Paclitaxel—breast cancer	0.00742	0.0424	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Docetaxel—breast cancer	0.00629	0.036	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Capecitabine—breast cancer	0.00609	0.0348	CcSEcCtD
Methotrimeprazine—Sudden death, cause unknown—Capecitabine—breast cancer	0.00519	0.0296	CcSEcCtD
Methotrimeprazine—CYP2D6—Doxorubicin—breast cancer	0.00501	0.0225	CbGbCtD
Methotrimeprazine—CHRM3—muscle of abdomen—breast cancer	0.00482	0.156	CbGeAlD
Methotrimeprazine—Necrotising colitis—Epirubicin—breast cancer	0.00424	0.0243	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Doxorubicin—breast cancer	0.00393	0.0224	CcSEcCtD
Methotrimeprazine—Priapism—Tamoxifen—breast cancer	0.00308	0.0176	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Toremifene—breast cancer	0.00278	0.0159	CcSEcCtD
Methotrimeprazine—Sudden death—Irinotecan—breast cancer	0.00205	0.0117	CcSEcCtD
Methotrimeprazine—Sudden death—Mitoxantrone—breast cancer	0.00205	0.0117	CcSEcCtD
Methotrimeprazine—Sudden death—Fluorouracil—breast cancer	0.00196	0.0112	CcSEcCtD
Methotrimeprazine—Liver injury—Tamoxifen—breast cancer	0.00177	0.0101	CcSEcCtD
Methotrimeprazine—Drug interaction—Tamoxifen—breast cancer	0.0016	0.00916	CcSEcCtD
Methotrimeprazine—Weight increased—Toremifene—breast cancer	0.00159	0.00907	CcSEcCtD
Methotrimeprazine—Jaundice—Toremifene—breast cancer	0.00151	0.00866	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Tamoxifen—breast cancer	0.00149	0.0085	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Melphalan—breast cancer	0.00146	0.00832	CcSEcCtD
Methotrimeprazine—Weight increased—Exemestane—breast cancer	0.0014	0.00798	CcSEcCtD
Methotrimeprazine—Sudden death—Capecitabine—breast cancer	0.00137	0.00784	CcSEcCtD
Methotrimeprazine—Jaundice—Ixabepilone—breast cancer	0.00126	0.00719	CcSEcCtD
Methotrimeprazine—Weight increased—Letrozole—breast cancer	0.00124	0.00709	CcSEcCtD
Methotrimeprazine—Weight increased—Anastrozole—breast cancer	0.00124	0.00709	CcSEcCtD
Methotrimeprazine—Jaundice—Anastrozole—breast cancer	0.00118	0.00677	CcSEcCtD
Methotrimeprazine—Weight increased—Raloxifene—breast cancer	0.00118	0.00673	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Fluoxymesterone—breast cancer	0.00113	0.00648	CcSEcCtD
Methotrimeprazine—Drug interaction—Gemcitabine—breast cancer	0.0011	0.0063	CcSEcCtD
Methotrimeprazine—Trifluoperazine—S100A4—breast cancer	0.00105	0.185	CrCbGaD
Methotrimeprazine—CHRM5—epithelium—breast cancer	0.00103	0.0332	CbGeAlD
Methotrimeprazine—Sudden death—Methotrexate—breast cancer	0.00102	0.00584	CcSEcCtD
Methotrimeprazine—Urinary retention—Goserelin—breast cancer	0.00098	0.0056	CcSEcCtD
Methotrimeprazine—CHRM5—skin of body—breast cancer	0.000976	0.0316	CbGeAlD
Methotrimeprazine—Constipation—Lapatinib—breast cancer	0.000934	0.00534	CcSEcCtD
Methotrimeprazine—Drug interaction—Paclitaxel—breast cancer	0.000922	0.00527	CcSEcCtD
Methotrimeprazine—ADRA1D—epithelium—breast cancer	0.000917	0.0297	CbGeAlD
Methotrimeprazine—Jaundice—Chlorambucil—breast cancer	0.00091	0.00521	CcSEcCtD
Methotrimeprazine—Constipation—Fulvestrant—breast cancer	0.000859	0.00491	CcSEcCtD
Methotrimeprazine—DRD5—female reproductive system—breast cancer	0.00085	0.0275	CbGeAlD
Methotrimeprazine—Weight increased—Tamoxifen—breast cancer	0.000849	0.00485	CcSEcCtD
Methotrimeprazine—Constipation—Toremifene—breast cancer	0.000847	0.00485	CcSEcCtD
Methotrimeprazine—Urinary retention—Thiotepa—breast cancer	0.000838	0.00479	CcSEcCtD
Methotrimeprazine—Photosensitivity—Fluorouracil—breast cancer	0.00083	0.00475	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Goserelin—breast cancer	0.000813	0.00465	CcSEcCtD
Methotrimeprazine—Weight increased—Goserelin—breast cancer	0.000811	0.00463	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Lapatinib—breast cancer	0.000804	0.0046	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Vinblastine—breast cancer	0.000799	0.00457	CcSEcCtD
Methotrimeprazine—Drowsiness—Goserelin—breast cancer	0.000794	0.00454	CcSEcCtD
Methotrimeprazine—Jaundice—Melphalan—breast cancer	0.000794	0.00454	CcSEcCtD
Methotrimeprazine—Drug interaction—Docetaxel—breast cancer	0.000781	0.00447	CcSEcCtD
Methotrimeprazine—Jaundice—Goserelin—breast cancer	0.000774	0.00443	CcSEcCtD
Methotrimeprazine—DRD5—female gonad—breast cancer	0.000773	0.025	CbGeAlD
Methotrimeprazine—Tachycardia—Letrozole—breast cancer	0.000756	0.00432	CcSEcCtD
Methotrimeprazine—Constipation—Exemestane—breast cancer	0.000746	0.00426	CcSEcCtD
Methotrimeprazine—ADRA2C—nipple—breast cancer	0.000746	0.0241	CbGeAlD
Methotrimeprazine—Hypersensitivity—Fulvestrant—breast cancer	0.00074	0.00423	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Docetaxel—breast cancer	0.000725	0.00414	CcSEcCtD
Methotrimeprazine—Dimetacrine—ACHE—breast cancer	0.00072	0.128	CrCbGaD
Methotrimeprazine—DRD5—endocrine gland—breast cancer	0.000719	0.0233	CbGeAlD
Methotrimeprazine—Constipation—Ixabepilone—breast cancer	0.000704	0.00402	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Irinotecan—breast cancer	0.000695	0.00397	CcSEcCtD
Methotrimeprazine—Weight increased—Thiotepa—breast cancer	0.000693	0.00396	CcSEcCtD
Methotrimeprazine—Somnolence—Anastrozole—breast cancer	0.000689	0.00394	CcSEcCtD
Methotrimeprazine—Somnolence—Letrozole—breast cancer	0.000689	0.00394	CcSEcCtD
Methotrimeprazine—ADRA1D—female reproductive system—breast cancer	0.000681	0.022	CbGeAlD
Methotrimeprazine—Agranulocytosis—Vinorelbine—breast cancer	0.000664	0.00379	CcSEcCtD
Methotrimeprazine—Constipation—Letrozole—breast cancer	0.000663	0.00379	CcSEcCtD
Methotrimeprazine—Constipation—Anastrozole—breast cancer	0.000663	0.00379	CcSEcCtD
Methotrimeprazine—Jaundice—Thiotepa—breast cancer	0.000662	0.00379	CcSEcCtD
Methotrimeprazine—CYP1A2—nipple—breast cancer	0.000647	0.0209	CbGeAlD
Methotrimeprazine—Hypersensitivity—Exemestane—breast cancer	0.000643	0.00367	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Thiotepa—breast cancer	0.000634	0.00362	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Ixabepilone—breast cancer	0.000606	0.00347	CcSEcCtD
Methotrimeprazine—HRH1—nipple—breast cancer	0.000606	0.0196	CbGeAlD
Methotrimeprazine—Weight increased—Mitoxantrone—breast cancer	0.000599	0.00342	CcSEcCtD
Methotrimeprazine—ADRA2A—nipple—breast cancer	0.000595	0.0192	CbGeAlD
Methotrimeprazine—Drowsiness—Mitoxantrone—breast cancer	0.000587	0.00335	CcSEcCtD
Methotrimeprazine—Liver injury—Epirubicin—breast cancer	0.000581	0.00332	CcSEcCtD
Methotrimeprazine—Photosensitivity—Capecitabine—breast cancer	0.00058	0.00332	CcSEcCtD
Methotrimeprazine—ADRA1D—endocrine gland—breast cancer	0.000577	0.0186	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Fluorouracil—breast cancer	0.000575	0.00329	CcSEcCtD
Methotrimeprazine—Jaundice—Irinotecan—breast cancer	0.000572	0.00327	CcSEcCtD
Methotrimeprazine—Jaundice—Mitoxantrone—breast cancer	0.000572	0.00327	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Anastrozole—breast cancer	0.000571	0.00326	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Paclitaxel—breast cancer	0.000567	0.00324	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Mitoxantrone—breast cancer	0.000547	0.00313	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Idarubicin—breast cancer	0.000542	0.0031	CcSEcCtD
Methotrimeprazine—Liver injury—Doxorubicin—breast cancer	0.000538	0.00307	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Gemcitabine—breast cancer	0.000533	0.00305	CcSEcCtD
Methotrimeprazine—ADRA1A—epithelium—breast cancer	0.000527	0.017	CbGeAlD
Methotrimeprazine—Agranulocytosis—Fluorouracil—breast cancer	0.000524	0.003	CcSEcCtD
Methotrimeprazine—Tachycardia—Melphalan—breast cancer	0.000507	0.0029	CcSEcCtD
Methotrimeprazine—HTR2C—female reproductive system—breast cancer	0.000504	0.0163	CbGeAlD
Methotrimeprazine—Tachycardia—Goserelin—breast cancer	0.000494	0.00283	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Paclitaxel—breast cancer	0.00049	0.0028	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Epirubicin—breast cancer	0.000489	0.0028	CcSEcCtD
Methotrimeprazine—Weight increased—Paclitaxel—breast cancer	0.000488	0.00279	CcSEcCtD
Methotrimeprazine—Urinary retention—Capecitabine—breast cancer	0.000484	0.00277	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Docetaxel—breast cancer	0.000481	0.00275	CcSEcCtD
Methotrimeprazine—CHRM1—female reproductive system—breast cancer	0.000476	0.0154	CbGeAlD
Methotrimeprazine—Constipation—Vinblastine—breast cancer	0.000467	0.00267	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Capecitabine—breast cancer	0.000465	0.00266	CcSEcCtD
Methotrimeprazine—CHRM3—adipose tissue—breast cancer	0.000464	0.015	CbGeAlD
Methotrimeprazine—Constipation—Tamoxifen—breast cancer	0.000453	0.00259	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Doxorubicin—breast cancer	0.000452	0.00259	CcSEcCtD
Methotrimeprazine—Somnolence—Goserelin—breast cancer	0.00045	0.00257	CcSEcCtD
Methotrimeprazine—ADRA2C—endometrium—breast cancer	0.00045	0.0146	CbGeAlD
Methotrimeprazine—CHRM2—endocrine gland—breast cancer	0.000443	0.0143	CbGeAlD
Methotrimeprazine—Tachycardia—Vinorelbine—breast cancer	0.000443	0.00253	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Chlorambucil—breast cancer	0.000439	0.00251	CcSEcCtD
Methotrimeprazine—Constipation—Goserelin—breast cancer	0.000433	0.00248	CcSEcCtD
Methotrimeprazine—Photosensitivity—Methotrexate—breast cancer	0.000432	0.00247	CcSEcCtD
Methotrimeprazine—CHRM3—female reproductive system—breast cancer	0.000426	0.0138	CbGeAlD
Methotrimeprazine—ADRA1A—adipose tissue—breast cancer	0.000426	0.0138	CbGeAlD
Methotrimeprazine—Tachycardia—Thiotepa—breast cancer	0.000423	0.00242	CcSEcCtD
Methotrimeprazine—DRD2—pituitary gland—breast cancer	0.000419	0.0136	CbGeAlD
Methotrimeprazine—HTR2A—embryo—breast cancer	0.000417	0.0135	CbGeAlD
Methotrimeprazine—ADRA2C—uterus—breast cancer	0.000415	0.0134	CbGeAlD
Methotrimeprazine—Weight increased—Docetaxel—breast cancer	0.000414	0.00237	CcSEcCtD
Methotrimeprazine—HRH1—epithelium—breast cancer	0.000408	0.0132	CbGeAlD
Methotrimeprazine—ADRA2C—pituitary gland—breast cancer	0.000407	0.0132	CbGeAlD
Methotrimeprazine—ADRA2C—adipose tissue—breast cancer	0.000406	0.0131	CbGeAlD
Methotrimeprazine—Photosensitivity—Epirubicin—breast cancer	0.000404	0.00231	CcSEcCtD
Methotrimeprazine—CHRM1—endocrine gland—breast cancer	0.000403	0.013	CbGeAlD
Methotrimeprazine—Hypersensitivity—Vinblastine—breast cancer	0.000402	0.0023	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Capecitabine—breast cancer	0.000402	0.0023	CcSEcCtD
Methotrimeprazine—Weight increased—Capecitabine—breast cancer	0.000401	0.00229	CcSEcCtD
Methotrimeprazine—Jaundice—Docetaxel—breast cancer	0.000395	0.00226	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Tamoxifen—breast cancer	0.000391	0.00223	CcSEcCtD
Methotrimeprazine—Constipation—Vinorelbine—breast cancer	0.000388	0.00222	CcSEcCtD
Methotrimeprazine—CHRM3—female gonad—breast cancer	0.000388	0.0125	CbGeAlD
Methotrimeprazine—Somnolence—Thiotepa—breast cancer	0.000385	0.0022	CcSEcCtD
Methotrimeprazine—Jaundice—Capecitabine—breast cancer	0.000383	0.00219	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Melphalan—breast cancer	0.000383	0.00219	CcSEcCtD
Methotrimeprazine—ADRA1A—adrenal gland—breast cancer	0.000382	0.0123	CbGeAlD
Methotrimeprazine—Agranulocytosis—Docetaxel—breast cancer	0.000378	0.00216	CcSEcCtD
Methotrimeprazine—Photosensitivity—Doxorubicin—breast cancer	0.000374	0.00214	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Goserelin—breast cancer	0.000373	0.00213	CcSEcCtD
Methotrimeprazine—Constipation—Thiotepa—breast cancer	0.00037	0.00212	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Capecitabine—breast cancer	0.000366	0.00209	CcSEcCtD
Methotrimeprazine—HRH1—endometrium—breast cancer	0.000366	0.0118	CbGeAlD
Methotrimeprazine—Tachycardia—Mitoxantrone—breast cancer	0.000365	0.00209	CcSEcCtD
Methotrimeprazine—ADRA2C—adrenal gland—breast cancer	0.000364	0.0118	CbGeAlD
Methotrimeprazine—CHRM3—endocrine gland—breast cancer	0.000361	0.0117	CbGeAlD
Methotrimeprazine—ADRA2A—endometrium—breast cancer	0.000359	0.0116	CbGeAlD
Methotrimeprazine—Tachycardia—Fluorouracil—breast cancer	0.00035	0.002	CcSEcCtD
Methotrimeprazine—HTR2A—epithelium—breast cancer	0.000341	0.011	CbGeAlD
Methotrimeprazine—ADRA2C—female gonad—breast cancer	0.000339	0.011	CbGeAlD
Methotrimeprazine—Hypersensitivity—Vinorelbine—breast cancer	0.000334	0.00191	CcSEcCtD
Methotrimeprazine—Somnolence—Irinotecan—breast cancer	0.000333	0.0019	CcSEcCtD
Methotrimeprazine—Somnolence—Mitoxantrone—breast cancer	0.000333	0.0019	CcSEcCtD
Methotrimeprazine—ADRA1A—endocrine gland—breast cancer	0.000331	0.0107	CbGeAlD
Methotrimeprazine—ADRA2A—uterus—breast cancer	0.000331	0.0107	CbGeAlD
Methotrimeprazine—HRH1—adipose tissue—breast cancer	0.00033	0.0107	CbGeAlD
Methotrimeprazine—ADRA2A—pituitary gland—breast cancer	0.000325	0.0105	CbGeAlD
Methotrimeprazine—DRD2—endocrine gland—breast cancer	0.000325	0.0105	CbGeAlD
Methotrimeprazine—Orthostatic hypotension—Epirubicin—breast cancer	0.000324	0.00185	CcSEcCtD
Methotrimeprazine—Somnolence—Gemcitabine—breast cancer	0.000324	0.00185	CcSEcCtD
Methotrimeprazine—ADRA2A—adipose tissue—breast cancer	0.000324	0.0105	CbGeAlD
Methotrimeprazine—Constipation—Irinotecan—breast cancer	0.00032	0.00183	CcSEcCtD
Methotrimeprazine—Constipation—Mitoxantrone—breast cancer	0.00032	0.00183	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Thiotepa—breast cancer	0.000319	0.00182	CcSEcCtD
Methotrimeprazine—Somnolence—Fluorouracil—breast cancer	0.000319	0.00182	CcSEcCtD
Methotrimeprazine—Constipation—Gemcitabine—breast cancer	0.000312	0.00178	CcSEcCtD
Methotrimeprazine—HRH1—female reproductive system—breast cancer	0.000303	0.0098	CbGeAlD
Methotrimeprazine—Orthostatic hypotension—Doxorubicin—breast cancer	0.0003	0.00171	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Methotrexate—breast cancer	0.000299	0.00171	CcSEcCtD
Methotrimeprazine—Tachycardia—Paclitaxel—breast cancer	0.000298	0.0017	CcSEcCtD
Methotrimeprazine—ADRA2A—female reproductive system—breast cancer	0.000298	0.00962	CbGeAlD
Methotrimeprazine—HRH1—adrenal gland—breast cancer	0.000296	0.00956	CbGeAlD
Methotrimeprazine—Drowsiness—Methotrexate—breast cancer	0.000292	0.00167	CcSEcCtD
Methotrimeprazine—CYP2E1—female reproductive system—breast cancer	0.000291	0.00941	CbGeAlD
Methotrimeprazine—ADRA2A—adrenal gland—breast cancer	0.00029	0.00939	CbGeAlD
Methotrimeprazine—CYP2E1—adrenal gland—breast cancer	0.000284	0.00919	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Epirubicin—breast cancer	0.00028	0.0016	CcSEcCtD
Methotrimeprazine—Weight increased—Epirubicin—breast cancer	0.000279	0.0016	CcSEcCtD
Methotrimeprazine—HTR2A—pituitary gland—breast cancer	0.000276	0.00894	CbGeAlD
Methotrimeprazine—HRH1—female gonad—breast cancer	0.000276	0.00891	CbGeAlD
Methotrimeprazine—Hypersensitivity—Mitoxantrone—breast cancer	0.000276	0.00158	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Irinotecan—breast cancer	0.000276	0.00158	CcSEcCtD
Methotrimeprazine—CYP1A2—endocrine gland—breast cancer	0.000274	0.00886	CbGeAlD
Methotrimeprazine—Drowsiness—Epirubicin—breast cancer	0.000274	0.00156	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Methotrexate—breast cancer	0.000273	0.00156	CcSEcCtD
Methotrimeprazine—Somnolence—Paclitaxel—breast cancer	0.000271	0.00155	CcSEcCtD
Methotrimeprazine—ADRA2A—female gonad—breast cancer	0.000271	0.00876	CbGeAlD
Methotrimeprazine—Jaundice—Epirubicin—breast cancer	0.000267	0.00152	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Fluorouracil—breast cancer	0.000264	0.00151	CcSEcCtD
Methotrimeprazine—Constipation—Paclitaxel—breast cancer	0.000261	0.00149	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Doxorubicin—breast cancer	0.000259	0.00148	CcSEcCtD
Methotrimeprazine—Weight increased—Doxorubicin—breast cancer	0.000258	0.00148	CcSEcCtD
Methotrimeprazine—HRH1—endocrine gland—breast cancer	0.000256	0.00829	CbGeAlD
Methotrimeprazine—Agranulocytosis—Epirubicin—breast cancer	0.000255	0.00146	CcSEcCtD
Methotrimeprazine—Drowsiness—Doxorubicin—breast cancer	0.000253	0.00145	CcSEcCtD
Methotrimeprazine—HTR2A—female reproductive system—breast cancer	0.000253	0.00818	CbGeAlD
Methotrimeprazine—Tachycardia—Docetaxel—breast cancer	0.000252	0.00144	CcSEcCtD
Methotrimeprazine—ADRA2A—endocrine gland—breast cancer	0.000252	0.00814	CbGeAlD
Methotrimeprazine—Ethopropazine—BCHE—breast cancer	0.000252	0.0446	CrCbGaD
Methotrimeprazine—HTR2A—adrenal gland—breast cancer	0.000247	0.00798	CbGeAlD
Methotrimeprazine—Jaundice—Doxorubicin—breast cancer	0.000247	0.00141	CcSEcCtD
Methotrimeprazine—CYP2E1—endocrine gland—breast cancer	0.000246	0.00797	CbGeAlD
Methotrimeprazine—Tachycardia—Capecitabine—breast cancer	0.000244	0.0014	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Doxorubicin—breast cancer	0.000236	0.00135	CcSEcCtD
Methotrimeprazine—CYP2D6—female reproductive system—breast cancer	0.000231	0.00745	CbGeAlD
Methotrimeprazine—Somnolence—Docetaxel—breast cancer	0.00023	0.00131	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Paclitaxel—breast cancer	0.000225	0.00129	CcSEcCtD
Methotrimeprazine—Constipation—Docetaxel—breast cancer	0.000221	0.00126	CcSEcCtD
Methotrimeprazine—ADRA2C—lymph node—breast cancer	0.000218	0.00705	CbGeAlD
Methotrimeprazine—HTR2A—endocrine gland—breast cancer	0.000214	0.00692	CbGeAlD
Methotrimeprazine—Constipation—Capecitabine—breast cancer	0.000214	0.00122	CcSEcCtD
Methotrimeprazine—Clomipramine—GSTP1—breast cancer	0.000211	0.0374	CrCbGaD
Methotrimeprazine—CYP2D6—female gonad—breast cancer	0.00021	0.00678	CbGeAlD
Methotrimeprazine—Triflupromazine—BCHE—breast cancer	0.000206	0.0365	CrCbGaD
Methotrimeprazine—Mepyramine—CYP2D6—breast cancer	0.000197	0.0349	CrCbGaD
Methotrimeprazine—CYP2D6—endocrine gland—breast cancer	0.000195	0.00631	CbGeAlD
Methotrimeprazine—Hypersensitivity—Docetaxel—breast cancer	0.000191	0.00109	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Capecitabine—breast cancer	0.000184	0.00105	CcSEcCtD
Methotrimeprazine—HRH1—lymph node—breast cancer	0.000177	0.00573	CbGeAlD
Methotrimeprazine—ADRA2A—lymph node—breast cancer	0.000174	0.00563	CbGeAlD
Methotrimeprazine—Tachycardia—Epirubicin—breast cancer	0.00017	0.000973	CcSEcCtD
Methotrimeprazine—Somnolence—Methotrexate—breast cancer	0.000166	0.000947	CcSEcCtD
Methotrimeprazine—Tachycardia—Doxorubicin—breast cancer	0.000158	0.000901	CcSEcCtD
Methotrimeprazine—Somnolence—Epirubicin—breast cancer	0.000155	0.000887	CcSEcCtD
Methotrimeprazine—Constipation—Epirubicin—breast cancer	0.000149	0.000853	CcSEcCtD
Methotrimeprazine—Somnolence—Doxorubicin—breast cancer	0.000143	0.00082	CcSEcCtD
Methotrimeprazine—Mequitazine—CYP2D6—breast cancer	0.000141	0.0251	CrCbGaD
Methotrimeprazine—Alimemazine—CYP3A4—breast cancer	0.000141	0.025	CrCbGaD
Methotrimeprazine—Constipation—Doxorubicin—breast cancer	0.000138	0.000789	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Methotrexate—breast cancer	0.000137	0.000785	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Epirubicin—breast cancer	0.000129	0.000735	CcSEcCtD
Methotrimeprazine—Diltiazem—CYP2D6—breast cancer	0.000127	0.0225	CrCbGaD
Methotrimeprazine—Mequitazine—CYP3A4—breast cancer	0.000121	0.0215	CrCbGaD
Methotrimeprazine—Hypersensitivity—Doxorubicin—breast cancer	0.000119	0.00068	CcSEcCtD
Methotrimeprazine—Diltiazem—CYP3A4—breast cancer	0.000109	0.0193	CrCbGaD
Methotrimeprazine—Pipotiazine—CYP2D6—breast cancer	0.000101	0.0178	CrCbGaD
Methotrimeprazine—Chlorpromazine—BCHE—breast cancer	9.95e-05	0.0176	CrCbGaD
Methotrimeprazine—Mesoridazine—CYP2D6—breast cancer	9.93e-05	0.0176	CrCbGaD
Methotrimeprazine—Prochlorperazine—CYP2D6—breast cancer	9.62e-05	0.017	CrCbGaD
Methotrimeprazine—Diltiazem—ABCB1—breast cancer	9.06e-05	0.0161	CrCbGaD
Methotrimeprazine—Fluphenazine—CYP2D6—breast cancer	8.7e-05	0.0154	CrCbGaD
Methotrimeprazine—Pipotiazine—CYP3A4—breast cancer	8.63e-05	0.0153	CrCbGaD
Methotrimeprazine—Prochlorperazine—CYP3A4—breast cancer	8.25e-05	0.0146	CrCbGaD
Methotrimeprazine—Triflupromazine—ABCB1—breast cancer	8.08e-05	0.0143	CrCbGaD
Methotrimeprazine—Clomipramine—CYP2D6—breast cancer	7.96e-05	0.0141	CrCbGaD
Methotrimeprazine—Acepromazine—ALB—breast cancer	7.83e-05	0.0139	CrCbGaD
Methotrimeprazine—Thioproperazine—ALB—breast cancer	7.65e-05	0.0136	CrCbGaD
Methotrimeprazine—Pipotiazine—ALB—breast cancer	7.53e-05	0.0133	CrCbGaD
Methotrimeprazine—Thioridazine—CYP2D6—breast cancer	7.49e-05	0.0133	CrCbGaD
Methotrimeprazine—Trimipramine—CYP2D6—breast cancer	7.32e-05	0.013	CrCbGaD
Methotrimeprazine—Promethazine—CYP2D6—breast cancer	7.05e-05	0.0125	CrCbGaD
Methotrimeprazine—Perphenazine—CYP2D6—breast cancer	6.88e-05	0.0122	CrCbGaD
Methotrimeprazine—Clomipramine—CYP3A4—breast cancer	6.82e-05	0.0121	CrCbGaD
Methotrimeprazine—Trimipramine—CYP3A4—breast cancer	6.28e-05	0.0111	CrCbGaD
Methotrimeprazine—Fluphenazine—ABCB1—breast cancer	6.21e-05	0.011	CrCbGaD
Methotrimeprazine—Clomipramine—ALB—breast cancer	5.95e-05	0.0105	CrCbGaD
Methotrimeprazine—Perphenazine—CYP3A4—breast cancer	5.9e-05	0.0105	CrCbGaD
Methotrimeprazine—Clomipramine—ABCB1—breast cancer	5.68e-05	0.0101	CrCbGaD
Methotrimeprazine—Chlorprothixene—ABCB1—breast cancer	5.66e-05	0.01	CrCbGaD
Methotrimeprazine—Chlorpromazine—CYP2D6—breast cancer	5.46e-05	0.00967	CrCbGaD
Methotrimeprazine—Imipramine—CYP2D6—breast cancer	5.43e-05	0.00962	CrCbGaD
Methotrimeprazine—Promazine—CYP3A4—breast cancer	5.32e-05	0.00942	CrCbGaD
Methotrimeprazine—Trimipramine—ABCB1—breast cancer	5.23e-05	0.00926	CrCbGaD
Methotrimeprazine—Promethazine—ABCB1—breast cancer	5.03e-05	0.00892	CrCbGaD
Methotrimeprazine—Trifluoperazine—ABCB1—breast cancer	4.97e-05	0.0088	CrCbGaD
Methotrimeprazine—Chlorpromazine—CYP3A4—breast cancer	4.68e-05	0.00829	CrCbGaD
Methotrimeprazine—Imipramine—CYP3A4—breast cancer	4.66e-05	0.00825	CrCbGaD
Methotrimeprazine—Chlorpromazine—ALB—breast cancer	4.08e-05	0.00723	CrCbGaD
Methotrimeprazine—Chlorpromazine—ABCB1—breast cancer	3.9e-05	0.0069	CrCbGaD
Methotrimeprazine—Imipramine—ABCB1—breast cancer	3.88e-05	0.00687	CrCbGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—VEGFA—breast cancer	2.49e-06	1.46e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CTNNB1—breast cancer	2.48e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TP53—breast cancer	2.48e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MMP9—breast cancer	2.48e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—HRAS—breast cancer	2.48e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	2.48e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MMP9—breast cancer	2.48e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CDKN1A—breast cancer	2.47e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—STAT3—breast cancer	2.47e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MMP9—breast cancer	2.47e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CDKN1A—breast cancer	2.47e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PTEN—breast cancer	2.47e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PTEN—breast cancer	2.46e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PTEN—breast cancer	2.46e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MMP9—breast cancer	2.46e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CDKN1A—breast cancer	2.46e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—PIK3CA—breast cancer	2.46e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MYC—breast cancer	2.46e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CAV1—breast cancer	2.46e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—VEGFA—breast cancer	2.46e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PTEN—breast cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MAPK8—breast cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TGFB1—breast cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CDKN1A—breast cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—AKT1—breast cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PTEN—breast cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	2.44e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MMP9—breast cancer	2.44e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—STAT3—breast cancer	2.43e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MMP9—breast cancer	2.43e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CDKN1A—breast cancer	2.43e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MAPK3—breast cancer	2.43e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PTEN—breast cancer	2.42e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	2.42e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PTEN—breast cancer	2.41e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MAPK8—breast cancer	2.41e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	2.41e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MAPK8—breast cancer	2.41e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—HRAS—breast cancer	2.41e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—AKT1—breast cancer	2.41e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—EGFR—breast cancer	2.4e-06	1.4e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—AKT1—breast cancer	2.4e-06	1.4e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MAPK8—breast cancer	2.4e-06	1.4e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—AKT1—breast cancer	2.39e-06	1.4e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MAPK8—breast cancer	2.39e-06	1.4e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CASP3—breast cancer	2.39e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—AKT1—breast cancer	2.39e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL2—breast cancer	2.38e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TP53—breast cancer	2.38e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—HRAS—breast cancer	2.37e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL6—breast cancer	2.37e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MAPK8—breast cancer	2.37e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—AKT1—breast cancer	2.36e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MAPK8—breast cancer	2.36e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MAPK3—breast cancer	2.36e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MYC—breast cancer	2.36e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—AKT1—breast cancer	2.36e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TGFB1—breast cancer	2.35e-06	1.37e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.35e-06	1.37e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—PIK3CA—breast cancer	2.34e-06	1.37e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—PIK3CA—breast cancer	2.33e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCND1—breast cancer	2.32e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—SRC—breast cancer	2.32e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MAPK3—breast cancer	2.32e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CD—breast cancer	2.32e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—JUN—breast cancer	2.32e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—PIK3CA—breast cancer	2.31e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—PIK3CA—breast cancer	2.31e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—EGFR—breast cancer	2.31e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL6—breast cancer	2.3e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	2.3e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MYC—breast cancer	2.3e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—ALB—breast cancer	2.29e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TGFB1—breast cancer	2.29e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—SRC—breast cancer	2.29e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—SRC—breast cancer	2.28e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—SRC—breast cancer	2.27e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—HRAS—breast cancer	2.27e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL6—breast cancer	2.27e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—KRAS—breast cancer	2.27e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—SRC—breast cancer	2.27e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TP53—breast cancer	2.27e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—VEGFA—breast cancer	2.26e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MYC—breast cancer	2.26e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MMP9—breast cancer	2.26e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TGFB1—breast cancer	2.25e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	2.25e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—SRC—breast cancer	2.25e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—EGFR—breast cancer	2.25e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PTEN—breast cancer	2.24e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—STAT3—breast cancer	2.24e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—SRC—breast cancer	2.24e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CG—breast cancer	2.24e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TP53—breast cancer	2.24e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TP53—breast cancer	2.24e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—VEGFA—breast cancer	2.23e-06	1.3e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—VEGFA—breast cancer	2.22e-06	1.3e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—VEGFA—breast cancer	2.22e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—EGFR—breast cancer	2.21e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—VEGFA—breast cancer	2.21e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—STAT3—breast cancer	2.21e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—STAT3—breast cancer	2.2e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MAPK8—breast cancer	2.19e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—STAT3—breast cancer	2.19e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—NOS3—breast cancer	2.19e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—AKT1—breast cancer	2.19e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—VEGFA—breast cancer	2.19e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—STAT3—breast cancer	2.19e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—VEGFA—breast cancer	2.18e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—KRAS—breast cancer	2.18e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL6—breast cancer	2.18e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—HRAS—breast cancer	2.17e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—STAT3—breast cancer	2.17e-06	1.26e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—STAT3—breast cancer	2.16e-06	1.26e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MAPK3—breast cancer	2.14e-06	1.25e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—HRAS—breast cancer	2.14e-06	1.25e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—HRAS—breast cancer	2.14e-06	1.25e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—AKT1—breast cancer	2.13e-06	1.24e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—KRAS—breast cancer	2.12e-06	1.24e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MAPK3—breast cancer	2.11e-06	1.23e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MAPK3—breast cancer	2.1e-06	1.23e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—AKT1—breast cancer	2.1e-06	1.22e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MAPK3—breast cancer	2.1e-06	1.22e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MAPK3—breast cancer	2.09e-06	1.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—KRAS—breast cancer	2.09e-06	1.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	2.09e-06	1.22e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MYC—breast cancer	2.08e-06	1.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—SRC—breast cancer	2.08e-06	1.22e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TGFB1—breast cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL6—breast cancer	2.07e-06	1.21e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MAPK3—breast cancer	2.07e-06	1.21e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MAPK3—breast cancer	2.06e-06	1.2e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—PIK3CA—breast cancer	2.06e-06	1.2e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MYC—breast cancer	2.05e-06	1.2e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL6—breast cancer	2.05e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL6—breast cancer	2.05e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MYC—breast cancer	2.05e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TGFB1—breast cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TGFB1—breast cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MYC—breast cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—EGFR—breast cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TGFB1—breast cancer	2.03e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MYC—breast cancer	2.03e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TGFB1—breast cancer	2.03e-06	1.18e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—VEGFA—breast cancer	2.03e-06	1.18e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CB—breast cancer	2.02e-06	1.18e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TP53—breast cancer	2.02e-06	1.18e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MYC—breast cancer	2.01e-06	1.18e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—AKT1—breast cancer	2.01e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TGFB1—breast cancer	2.01e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MYC—breast cancer	2.01e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—STAT3—breast cancer	2.01e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTGS2—breast cancer	2e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—EGFR—breast cancer	2e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—PIK3CA—breast cancer	2e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TGFB1—breast cancer	2e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—EGFR—breast cancer	2e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—EGFR—breast cancer	1.99e-06	1.16e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—EGFR—breast cancer	1.99e-06	1.16e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—EGFR—breast cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CD—breast cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—EGFR—breast cancer	1.96e-06	1.15e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	1.95e-06	1.14e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ALB—breast cancer	1.94e-06	1.13e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TP53—breast cancer	1.94e-06	1.13e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—HRAS—breast cancer	1.93e-06	1.13e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—KRAS—breast cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MAPK3—breast cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—AKT1—breast cancer	1.91e-06	1.12e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—AKT1—breast cancer	1.9e-06	1.11e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—KRAS—breast cancer	1.89e-06	1.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PIK3CA—breast cancer	1.89e-06	1.11e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—KRAS—breast cancer	1.89e-06	1.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—AKT1—breast cancer	1.89e-06	1.1e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—AKT1—breast cancer	1.89e-06	1.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TP53—breast cancer	1.89e-06	1.1e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—KRAS—breast cancer	1.88e-06	1.1e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—KRAS—breast cancer	1.88e-06	1.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MYC—breast cancer	1.86e-06	1.09e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TGFB1—breast cancer	1.86e-06	1.09e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—KRAS—breast cancer	1.86e-06	1.09e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—NOS3—breast cancer	1.86e-06	1.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TP53—breast cancer	1.86e-06	1.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—KRAS—breast cancer	1.85e-06	1.08e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—HRAS—breast cancer	1.85e-06	1.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL6—breast cancer	1.85e-06	1.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—EGFR—breast cancer	1.82e-06	1.07e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—HRAS—breast cancer	1.8e-06	1.05e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—HRAS—breast cancer	1.77e-06	1.04e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL6—breast cancer	1.77e-06	1.04e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—PIK3CA—breast cancer	1.77e-06	1.03e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTEN—breast cancer	1.75e-06	1.02e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PIK3CA—breast cancer	1.74e-06	1.02e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PIK3CA—breast cancer	1.74e-06	1.02e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PIK3CA—breast cancer	1.74e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PIK3CA—breast cancer	1.73e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL6—breast cancer	1.73e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PIK3CA—breast cancer	1.72e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—KRAS—breast cancer	1.72e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CB—breast cancer	1.71e-06	1e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TP53—breast cancer	1.71e-06	9.99e-06	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PIK3CA—breast cancer	1.71e-06	9.98e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—AKT1—breast cancer	1.7e-06	9.95e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	1.7e-06	9.95e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTGS2—breast cancer	1.7e-06	9.92e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL6—breast cancer	1.7e-06	9.92e-06	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—AKT1—breast cancer	1.69e-06	9.84e-06	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TP53—breast cancer	1.68e-06	9.83e-06	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TP53—breast cancer	1.68e-06	9.81e-06	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TP53—breast cancer	1.67e-06	9.78e-06	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TP53—breast cancer	1.67e-06	9.75e-06	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TP53—breast cancer	1.65e-06	9.65e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TP53—breast cancer	1.65e-06	9.62e-06	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—AKT1—breast cancer	1.64e-06	9.56e-06	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—HRAS—breast cancer	1.64e-06	9.55e-06	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—HRAS—breast cancer	1.61e-06	9.4e-06	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—HRAS—breast cancer	1.61e-06	9.38e-06	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—HRAS—breast cancer	1.6e-06	9.35e-06	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HRAS—breast cancer	1.6e-06	9.32e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—AKT1—breast cancer	1.59e-06	9.3e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	1.58e-06	9.24e-06	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HRAS—breast cancer	1.58e-06	9.23e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HRAS—breast cancer	1.58e-06	9.2e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—AKT1—breast cancer	1.57e-06	9.15e-06	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL6—breast cancer	1.57e-06	9.14e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—AKT1—breast cancer	1.55e-06	9.03e-06	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL6—breast cancer	1.54e-06	9e-06	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL6—breast cancer	1.54e-06	8.98e-06	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL6—breast cancer	1.53e-06	8.95e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TP53—breast cancer	1.53e-06	8.94e-06	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL6—breast cancer	1.53e-06	8.92e-06	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL6—breast cancer	1.51e-06	8.83e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL6—breast cancer	1.51e-06	8.81e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTEN—breast cancer	1.48e-06	8.65e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HRAS—breast cancer	1.46e-06	8.55e-06	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—AKT1—breast cancer	1.44e-06	8.44e-06	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—AKT1—breast cancer	1.42e-06	8.3e-06	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—AKT1—breast cancer	1.42e-06	8.29e-06	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—AKT1—breast cancer	1.42e-06	8.28e-06	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—AKT1—breast cancer	1.41e-06	8.26e-06	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—AKT1—breast cancer	1.41e-06	8.23e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL6—breast cancer	1.4e-06	8.19e-06	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—AKT1—breast cancer	1.4e-06	8.15e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—AKT1—breast cancer	1.39e-06	8.13e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—AKT1—breast cancer	1.29e-06	7.55e-06	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CA—breast cancer	1.23e-06	7.2e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CA—breast cancer	1.04e-06	6.1e-06	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—AKT1—breast cancer	1.01e-06	5.88e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—AKT1—breast cancer	8.54e-07	4.99e-06	CbGpPWpGaD
